Pheon Therapeutics enters into license agreement with Biocytogen Pharmaceuticals
Exclusive license agreement for an oncological target antibody to develop best-in-class ADC
London, UK and Beijing, China, 5 July 2023 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate(ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces an exclusive licence agreement with Biocytogen Pharmaceuticals (Beijing) Co. Ltd. (Biocytogen), a global biotech company focused on the discovery of novel antibody therapeutics. Under the terms of the agreement, Pheon will develop and commercialize an antibody developed using Biocytogen’s proprietary RenMiceTM platforms. Biocytogen will receive an upfront payment and is eligible for development and commercial milestone payments as well as single-digit royalties on net sales.
